Vyriad, Inc.
Privately-held clinical stage (phase 2) biotechnology company developing oncolytic virus-based cancer therapies and in vivo targeted delivery of genetic medicine (CAR-T) platforms.
)
January 11-14, 2027 | San Francisco
January 11-14, 2027 | San Francisco
)
)
January 11-14, 2027 | San Francisco
){kind=logo}
)